GPC Biotech AG (NASDAQ: GPCB)

GPC Biotech AG (NASDAQ: GPCB), a biopharmaceutical company, is focused on discovering, developing, and commercializing anticancer drugs. Its pipeline of products include satraplatin, an oral platinum-based anticancer agent that is in phase 1 and 2 trials; RGB-286638, a broad-spectrum kinase inhibitor that has completed pre-clinical testing; and RGB-344064, a selective inhibitor of cyclin-dependent kinases that is in pre-clinical testing. For further information, visit the Company’s web site at www.gpc-biotech.com.